Skip to main content
SpringerLink
Log in

What Is the Ongoing Recommendation in the Management of Rectal Cancer?

  • Chapter
  • First Online:
Multidisciplinary Management of Rectal Cancer

  • 1002 Accesses

Abstract

During the past 20 years, we have seen major changes in the way patients with rectal cancer are investigated and treated. The key components are the improvements in preoperative staging, in surgical technique and histopathological assessment of the resected specimen, and in combining multimodality treatments to ameliorate the long-term outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Sauer R, Becker H, Hoyhenberger W et al (2004) For the German rectal cancer study group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740

    Article  CAS  PubMed  Google Scholar 

  2. Gérard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625

    Article  PubMed  Google Scholar 

  3. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L et al (2006) EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123

    Article  CAS  PubMed  Google Scholar 

  4. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–23.30

    Article  CAS  PubMed  Google Scholar 

  5. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T et al (2007) Dutch colorectal cancer group the TME trial after a median follow-up of six years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701

    Article  PubMed  Google Scholar 

  6. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S et al (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomized trial. Lancet 373:811–820

    Article  PubMed  PubMed Central  Google Scholar 

  7. Braendengen M, Tveit KM, Berglund A et al (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26:3687–3694

    Article  CAS  PubMed  Google Scholar 

  8. Valentini V, Aristei C, Glimelius B et al (2009) multidisciplinary rectal cancer management: second European rectal cancer consensus conference (EURECA-CC2). Radiother Oncol 92(2):148–163

    Article  PubMed  Google Scholar 

  9. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision-making. Ann Oncol 23(10):2479–2516

    Article  CAS  PubMed  Google Scholar 

  10. van de Velde C, Boelens P, Borras J et al (2013) EURECCA colorectal: multidisciplinary management: European consensus conference colon and rectum. Eur J Cancer 49(13):2784–2790

    Article  PubMed  Google Scholar 

  11. Roh MS, Colangelo LH, O'Connell MJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124–5130

    Article  PubMed  PubMed Central  Google Scholar 

  12. Roh JK, Yothers G (2011) The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 29:abstr 3503

    Google Scholar 

  13. O’Connell MJ, Martenson JA, Wieand HS et al (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–507

    Article  PubMed  Google Scholar 

  14. Hofheinz RD, Wenz F (2011) Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): long-term results of a randomized, phase III trial. J Clin Oncol 29:abstr 3504

    Google Scholar 

  15. Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644

    Article  CAS  PubMed  Google Scholar 

  16. Bystrom P, Frodin JE, Berglund A, Wilking N, Glimelius B (2004) Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer. Radiother Oncol 70:171–175

    Article  CAS  PubMed  Google Scholar 

  17. Schiebe ME, Reese T, Wenz F et al (2002) Phase I study of oral uracil and Tegafur plus leucovorin and pelvic radiation in patients with recurrent rectal cancer. Anti-Cancer Drugs 13:1005–1009

    Article  CAS  PubMed  Google Scholar 

  18. Jakobsen A, Appelt AL (2011) The dose-effect relationship in preoperative chemoradiation of locally advanced rectal cancer: preliminary results of a phase III trial. J Clin Oncol 29:abstr 3512

    Google Scholar 

  19. Vestermark LW, Jacobsen A, Qvortrup C et al (2008) Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC). Acta Oncol 47:428–433

    Article  CAS  PubMed  Google Scholar 

  20. Roedel C, Becker H (2011) Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol 29:abstr LBA3505

    Google Scholar 

  21. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029

    Article  PubMed  Google Scholar 

  22. Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

“The authors would like to thank Giuditta Chiloiro (Università Cattolica del Sacro Cuore, Radiation Oncology Department, Rome, Italy) for the excellent support during manuscript editing”

Author information

Authors and Affiliations

  1. Università Cattolica del Sacro Cuore, Radiation Oncology Department, Rome, Italy

    V. Valentini

  2. University clinic Halle(Saale), Department for Internal Medicine, Oncology and Hematology, Halle, Germany

    Hans-Joachim Schmoll

  3. Leiden University Medical Center, Department of Surgery, Leiden, The Netherlands

    C. J. H. van de Velde

Authors
  1. V. Valentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans-Joachim Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. J. H. van de Velde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. J. H. van de Velde .

Editor information

Editors and Affiliations

  1. Dept. of Radiation Oncology, Università Cattolica S Cuore, Rome, Italy

    Vincenzo Valentini

  2. Head, Div. Clinical Oncology Research, University Clinic Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Sachsen-Anhalt, Germany

    Hans-Joachim Schmoll

  3. Department of Surgery, Leiden Univ Med Ctr, Leiden, The Netherlands

    Cornelis J. H. van de Velde

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag Berlin Heidelberg

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Valentini, V., Schmoll, HJ., van de Velde, C.J.H. (2018). What Is the Ongoing Recommendation in the Management of Rectal Cancer?. In: Valentini, V., Schmoll, HJ., van de Velde, C. (eds) Multidisciplinary Management of Rectal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-43217-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43217-5_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43215-1

  • Online ISBN: 978-3-319-43217-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation